

Cumulative Index 1986

Volume 13

<i>March</i>	PERINATAL NUTRITION
<i>June</i>	THE TINY BABY
<i>September</i>	TERATOLOGY
<i>December</i>	CRITICAL CARE IN OBSTETRICS

Note: Page number of article titles are in **boldface type**.

- Abdomen, circumference, in evaluation of fetal growth, 20
- malformations in thalidomide syndrome, 570
- Abortion, septic, and disseminated intravascular coagulation, 712-713
- Absorption deficiencies, 46-50
- Acid-base homeostasis, in VVLBW infants, 385
- Adult respiratory distress syndrome, and colloid osmotic pressure, 838-839
- in septic shock, 748
- Afterload, in invasive hemodynamic monitoring, 771-772
- Agent Orange teratogenicity, 663
- Alanine, 103
- Albumin, in premature infants, 84, 130-131
- Alcohol teratogenicity, 654-659
- Alpha-ketoisocaproate, 100-101
- Alpha-ketoisovalerate, 100-101
- Amino acid(s), branched chain, 98-101
- essential, 97-103
- "ideal" intake of, 97
- intake, assessment of methods, 95
- nonessential, 100, 103-104
- nonradioactively labeled, in protein flux studies, 93
- requirements, in premature infants, 95-104
- umbilical uptake of, by fetus, 96-07
- Amino acid solution, 100, 104
- metabolic effects of, 69-70
- ¹³C-amino acids, estimation of protein turnover, 129
- ¹⁵N-amino acids, in protein requirement studies, 125-127
- Aminoglycosides, and premature kidney function, 394-395
- C-amino peptide, in amniotic fluid, 16
- Aminopterin teratogenicity, 660
- Amnion, early rupture, and limb reduction defects, 582-585
- Amnionitis, and outcome of 501- to 1000-gm newborns, 273, 281-282
- Amniotic fluid, embolism, **801-811**
- clinical presentation, 807
- coagulopathy, 806
- diagnosis, 808
- and disseminated intravascular coagulation, 714-716
- experimental animal models, 802-804
- historical considerations, 801-802
- human data, 804-806
- management protocol, 808-809

- Amniotic fluid (*Continued*)
 embolism, treatment, 808
 volume, 21-22
- Amylase deficiency, pancreatic, 49-50
- Amylases, pancreatic, salivary, and mammary, 41
- Analgesia, epidural, and antihypertensive therapy, 786-787
- Androgen teratogenicity, 660
- Animal models for teratogenicity of environmental agents, 610-611
- Anorexia nervosa, maternal, total parenteral nutrition in, 68
- Antepartum care, of sickle cell crisis, 858-862
- Anthropometric measurements, in pediatric patient, 74
 in pregnancy, 64
 in premature infants, 79-83
- Anticoagulation, with heparin, 728-731
 with warfarin, 731-732
- Antimicrobial therapy, in septic shock, 748-749
- Antineoplastic drugs, teratogenicity of, 659-660
- Antithyroid drugs, teratogenicity of, 670
- Aortic stenosis during pregnancy, 699-700
- Apgar scores, and outcome of 501- to 1000-gm newborns, 277, 282
- Arrhythmias, cardiac, and betamimetic therapy for preterm labor inhibition, 848-849
 in tiny, premature infants, 339-350
 bradyarrhythmias, 340-341
 bradycardia in, 347-348
 fetal arrhythmias, 345-347
 intraventricular conduction defects in, 343
 management of, 347
 mechanism and etiology of, 339
 premature atrial contractions, 341
 premature beats and tachycardias, 341
 premature ventricular contractions, 343
 supraventricular tachycardia, 341-343, 348
 ventricular tachycardia, 343, 349
- Arteriography, pulmonary, in thromboembolic disease, 727-728
- Aspirin teratogenicity, 673-674
- Atrial contractions, premature, in tiny premature infant, 341
- Attorney for plaintiff, 523-525
- Bacterial endocarditis prophylaxis, in pregnancy, 702-703
- Barotrauma, in bronchopulmonary dysplasia in tiny infant, 317
- Basal energy expenditure, in pregnancy, 65
- Beats, premature, and tachycardias, in tiny premature infant, 341
- Beta-adrenergic agonists, and premature kidney, 390-391
- Betamimetic therapy for preterm labor inhibition, 843-852
 cardiac arrhythmias, 848-849
 cerebral ischemia, 849-850
 circulatory system, 843
 hyperglycemia, 850
 hypotension, 850-851
 myocardial ischemia, 847-848
 pulmonary edema, 844-845
 renal function, 845-847
- Bilirubin binding, effect of lipid emulsions, 147-149
- Biochemical tests, in protein energy malnutrition, 83-84
- Biometry, fetal, ultrasound diagnosis, 599-601
- Biparietal diameter, fetal, 19-20
- Birth defects, chronic disease morbidity, 546
 identification problems, 552-553
 case reports, 552
 etiologic studies, 552-553
 incidence trends, 546-550
 and infant mortality, 545-546
 Years of Potential Life Lost, 545-546
- Birth weight, distribution of, and VVLBW rate, 236-240
 and maternal age, 239
 and outcome of 501- to 1000-gm newborns, 280-281
 and prenatal care, 240
- Blood, colloid osmotic pressure, normal values, 831-833
- Blood flow, measurements, 23-24
- Blood loss, in pregnancy, physiologic changes, 757
- Blood pressure, and volume expansion in preeclampsia, 785
 in VVLBW infants, 330-333
- Blood vessel malformations in thalidomide syndrome, 569-570
- Body fluid compartments in VVLBW infants, 403-417
 data review, 405-416
 methodology of, 403-405
- Bowel, normal, anatomic and functional development, 163-164
 short. See *Short bowel syndrome*.
- Bradyarrhythmias, in tiny premature infant, 340-341
- Bradycardia, in tiny premature infant, 347-348
- Breast milk. See *Milk(s), human*.
- Breast-feeding, decline in, 112
 historic perspectives, 111-112
 immunologic and host resistance factors, 112-113

- of premature infant, 111-122
 - recent trends back to, 112
 - Breath hydrogen test, 45-46
 - Bronchodilators, in bronchopulmonary dysplasia, 321
 - Bronchopulmonary dysplasia in tiny infant, 293-294, 315-326
 - history and definition, 315-319
 - barotrauma, 317
 - developmental immaturity, 318
 - etiology of, 317
 - oxygen use, 317
 - predisposition to, 318-319
 - long-term outcome, 324
 - management of, 320-322
 - bronchodilators, 321
 - fluid management, 321-322
 - steroids, 321
 - supportive care, 322
 - ventilator, 320-321
 - nutrition in, 320
 - postdischarge management, 322-324
 - prevention or ameliorization of, 319-320
 - supportive care, 320
 - ventilatory and oxygen supplementation, 319-320
- Caffeine teratogenicity, 674
- Calcium, absorption, effect of carbohydrate intake on, 44
- in human milk, 115
 - loss, in short bowel syndrome, 166
 - in parenteral nutrition of VVLBW infants, 430
 - and phosphate homeostasis, in VVLBW infants, 386-387
- Calorimetry, portable indirect, in pregnancy, 64-65
- Captopril, and premature kidney, 391
- Carbohydrate(s), absorption, and gastrointestinal physiology, 38-42
- colonic salvage of, in infancy, 42
 - digestion, 37-55
 - historical perspective on, 37-38
 - gastric emptying of, in newborn period, 38
 - in infant formulas, 42-44
 - intake, effect of, on calcium and electrolyte absorption, 44
 - malabsorption, clinical tests of, 45-46
 - in VVLBW infants, nutritional requirements, 436
 - in parenteral nutrition, 425-426
- Carbon dioxide, transcutaneous measurements in VVLBW infants, 334
- Carcinogenesis of in utero ionizing radiation, 617-643
- Cardiac disease, structural, 695-703
- bacterial endocarditis, prophylaxis for, 702-703
 - hemodynamic changes, 695-700
 - aortic stenosis, 699-700
 - mitral stenosis, 698-699
 - myocardial infarction, 702
 - pulmonary hypertension, 700-702
 - Cardiac function curves, in severe preeclampsia, 790
 - Cardiac output in preeclampsia, hypertension in, 792-793
 - and regional perfusion, 791-792
 - and systemic vascular resistance, 791
 - and volume expansion in preeclampsia, 785
 - Cardiovascular monitoring, and obstetrics, 776-777
 - Carnitine, in lipid catabolism, 142-144
 - Carnitine acyltransferase, 136
 - Catheterization of pulmonary artery, in severe pregnancy-induced hypertension, 787-788, 795-796
 - Cephalometry, 19-20
 - Cerebral ischemia, and betamimetic therapy for preterm labor inhibition, 849-850
 - Cholestasis, with parenteral nutrition in VVLBW infants, 430-431
 - Circulatory system, and betamimetic therapy for preterm labor inhibition, 843
 - malformations in thalidomide syndrome, 569-570
 - volume restoration of in hemorrhagic shock, 758-760
 - Clinical patterns of thalidomide syndrome, 556-558
 - Coagulation, disseminated intravascular, 705-717
 - diagnosis, 708-709
 - due to amniotic fluid embolus, 714-716
 - due to fetal death syndrome, 713-714
 - due to placental abruption, 711-712
 - due to preeclampsia, 710-711
 - due to septic abortion, 712-713
 - pathophysiology, 707
 - treatment, 709-710
 - lipid emulsion effects, 153
 - Coagulopathy, for amniotic fluid embolism, 806
 - Colloid osmotic pressure, in pregnancy, 827-842
 - calculation and measurement, 829-831
 - clinical applications, 836-839
 - adult respiratory distress syndrome, 838-839
 - and fluid therapy, 833-834, 837-838
 - pulmonary capillary wedge pressure gradient, 836-837
 - collection techniques, 831
 - definition of, 827-828
 - and mortality, 839-840

- Colloid osmotic pressure (*Continued*)
 normal values in blood and interstitium, 831-833
 in postpartum period, 834
 in pregnancy-induced hypertension, 835-836
 Starling's law, 828-829
 and tocolytic therapy, 835
 Communication, in medicolegal cases, 513
 Conduction defects, intraventricular, in tiny premature infant, 343
 Cord prolapse, and outcome of 501- to 1000-gm newborns, 271, 281
 Corticosteroids for lung maturation, in VVLBW fetus, 257-258
 Cost of care of VVLBW infants, 463-478
 cost-benefit analysis, 474-475
 duration of hospitalization, 467-468
 economic considerations, 468-474
 methodology of study program, 465-466
 mortality and survival, 466-467
 program description, 464-465
 Coumarin derivatives, teratogenicity of, 661
 C-peptide, in macrosomic infants, 78
 in newborns with septicemia, 83-84
 Cranial nerve malformations in thalidomide syndrome, 568-569
 Creatinine, 3-methyl histidine, ratio in amniotic fluid, 15-16
 Cyclophosphamide teratogenicity, 661-662
 Cysteine, 102
 Cystine aminopeptidase, 17
- Death rates, epidemiologic study of, 235
 weight-specific, 240-242
 Defendant in congenital malformation lawsuits, 507-508, 522
 Delivery, preterm, obstetric management of, 259-261
 Delivery room management, of respiration in VVLBW infants, 286-288
 Developmental immaturity, and bronchopulmonary dysplasia in tiny infant, 318
 Diabetic mothers, infants of, 77
 Diet therapy, in short bowel syndrome, 168
 Diethylstilbestrol teratogenicity, 662
 Digestive enzymes, intestinal, development of, 164
 Diphenylhydantoin teratogenicity, 662-663
 Disaccharidase(s), activity in intestine, 46, 47
 deficiencies, 48-49
 development of, in small intestine, 38-41
 Disaccharide intolerance, secondary, 49
 Dopamine, and premature kidney function, 392-393
 Doppler flow studies, principles of, 23
 Down's syndrome, incidence trends, 550
- Drug therapy, for hemorrhagic shock, 760-761
- Ectopic tubal gestation, and limb reduction defects, 578-579
 Education about human malformations, 501
 Electrolyte absorption, carbohydrate effects, 44
 Embolism, amniotic fluid, and disseminated intravascular coagulation, 714-716
 See also *Amniotic fluid embolism*.
 Embryo, and x-ray, microwave, and ultrasound exposure, 615-648
 counseling pregnant woman exposed to radiation, 634-639
 exposure from radiation therapy, 639-640
 human radiation teratogenesis, 619-628
 microwave and ultrasound, 642-643
 oncogenic effect of prenatal radiation, 628-634
 ovarian and uterine exposure to radiation, 640-642
 Energy utilization, "optimal," 145-146
 Environmental agents, teratogenicity of, 609-613
 animal testing, 610-611
 classification, 609-610
 drugs and chemicals, 649-687
 alcohol, 654-659
 aminopterin and methotrexate, 660
 androgens, 660
 antineoplastic drugs, 659-660
 coumarin derivatives, 661
 cyclophosphamide, 661-662
 diethylstilbestrol, 662
 diphenylhydantoin, 662-663
 herbicides: Agent Orange, 663
 lithium carbonate, 663-664
 mechanisms, 649-654
 methylmercury, 664
 nonprescription drugs and products, 673-674
 oxazolidine-2,4-diones (trimethadione, paramethadione), 664-665
 polychlorinated biphenyls, 665-666
 preconception exposures to noninfectious agents, 675
 progestins (female sex hormones), 666-667
 radiation, 667-668
 substance abuse: street drugs, 668
 teratogenic conditions acting on humans, 670-675
 tetracycline, 669
 thalidomide, 669-670
 thyroid:iodine deficiency, iodides, radioiodine, anti-thyroid drugs, 670
 evaluation methods, 611-612

- Epidemiology, of human malformations, 492-493
 teratogenicity of environmental agents, 611-612
 of very low and very very low birth weight infants, 233-250
 birth weight distribution and VVLBW rate, 236-240
 definition of terms, 233-235
 less than 500-gm births, 242-244
 measures of association, 235-236
 morbidity and long-term outcome, 245-246
 place of birth for VLBW infants, 244
 postneonatal mortality, 244-245
 prematurity prevention, and "nine by ninety," 246-248
 weight-specific death rates, 240-242
- Estril, 14-15
 excretion, low, total parenteral nutrition in, 68-69
- Ethical issues in caring for tiny infants, 479-486
 gnosis, 481-482
 individual and society, 484
 rejecting ethics of necessity, 482-484
 responsivity ethics, 485
- Etiology, of birth defects, 550-552
 costs and difficulties of studies, 553
 exposure/case definitions, 552-553
 of congenital human malformations, 493-495, 508-509
 of fatty liver in pregnancy, 813-825
 of septic shock in obstetrics, 741-742
- Expert witness, case study, 530-536
 in congenital malformation lawsuits, 508, 522-523, 529-538
 physician as, 522-523
 quality of testimony, 537-538
 responsibility failures, 536-537
- Exposure risks in thalidomide syndrome, 556
- Extrapulmonary complications in VVLBW infants, 294
- Familial fetal growth heterogeneity, 13
- Family history, limb reduction defects, 576-577
- Fat, total body, assessment of, in premature infant, 81
- Fat emulsions, parenteral, risk in pregnancy, 69
- Fatty acids, essential, deficiency of, 144-145
 long-chain, in circulation, 134
- Fatty liver, acute, of pregnancy, 813-825
 clinical presentation, 819-821
 diagnostic tests, 820-821
 history, 819
 laboratory tests, 820
 physical examination, 819
 differential diagnosis, 817-818
 historical perspective, 813-814
 pathogenesis, 814-815
 pathology, 816-817
 pathophysiology, 815-816
 treatment, 821-823
 delivery, 821-822
 interdictive care, 822-823
 supportive care, 822
- Female sex hormones, teratogenicity of, 666-667
- Fetal death syndrome, and disseminated intravascular coagulation, 713-714
- Fetus, arrhythmias in, 345-347
 biometry, ultrasound diagnosis, 599-601
 body composition, amino acid requirements, 95-96
 constraint, and limb reduction defects, 575-591
 family history, 576-577
 teratogenic history, 577-578
 uterine environments, 578-585
 and vascular disruption, 585-589
 distress, and outcome of 501- to 1000-gm newborns, 275, 282
 growth, 73-74
 assessment of, 3-35
 biochemical techniques for evaluating, 14-19
 clinical parameters for evaluating, 13-14
 epidemiologic evaluation of, 9-13
 maternal malnutrition and, 61-63
 quality of, neonatal assessment of, 75-78
 regulation of, in growth inhibition, 8
 retardation, risk factors for, total parenteral nutrition in, 68
 role of oxygen on, 191-196
 ultrasonography in evaluation of, 19-24
 nutrition of, methods for assessing, 80
 renal function in, 377-378
 structural defects, ultrasound diagnosis, 593-607
 absence of normally present structure, 593-596
 biometry abnormalities, 599-601
 dilatation behind obstruction, 598-599
 herniations through structural defects, 597-598
 motion abnormalities, 602
 presence of additional structure, 596-597
 and x-ray, microwave, and ultrasound exposure, 615-648
 counseling pregnant woman exposed to radiation, 634-639
 exposure from radiation therapy, 639-640
 human radiation teratogenesis, 619-628

Fetus (*Continued*)

- and x-ray, microwave and ultrasound, 642-643
- oncogenic effect of prenatal radiation, 628-634
- ovarian and uterine exposure to radiation, 640-642
- Fibrinogen scanning, in thromboembolic disease, 725
- Fluid management, in bronchopulmonary dysplasia in tiny infant, 321-322
- and colloid osmotic pressure, 833-834, 837-838
- Foam stability index, and phosphatidylglycerol, 18-19
- Foods for full-term infants, 92
- Formulas, infant, carbohydrate composition of, 42-44
- Fundal height, and fetal growth, 13-14
- Furosemide, and premature kidney function, 391-392
- Gastrointestinal disorders, and outcome of 501- to 1000-gm newborns, 279, 283
- Glomerular filtration in VVLBW infants, 378-382
- Glucosylase, development of, 41-42
- Glucose, excretion in VVLBW infants, 387-388
- metabolism, effect of lipid emulsions on, 147
- in pregnancy, 60
- Glucose-galactose malabsorption, primary, 46
- Glucose system, vs. lipid system, 145-146
- Glucose tolerance testing, 17-18
- Glutamate, 103
- Glutamin, 103
- ¹⁵N-glycine, in studies of protein requirements, 127-128
- Glycoprotein, pregnancy-specific beta, 17-18
- Glycosuria, in total parenteral nutrition, 67
- Growth, comparable to in utero, protein infusion for, 146
- embryonic-fetal, cell number and rate of mitosis, 4
- fetal. *See Fetus.*
- inhibition, nature and timing of, 5-9
- intrauterine, biometry of, 3-5
- dysfunction of, 3-5
- fetal hormone effects, 11, 12
- malformations in thalidomide syndrome, 567
- Growth curves, measurement of in pediatric patient, 74

- Head circumference, abdominal circumference ratio, 20
- midarm circumference ratio, 76-78
- of premature infant, 75
- Head growth, in premature infant, 81
- Heart malformations in thalidomide syndrome, 569-570
- Heart rate, in VVLBW infants, 327-330
- Hemodynamics, invasive monitoring of, 765-779
- cardiovascular monitoring and obstetrics, 776-777
- clinical investigations, 777
- data collection, 768-769
- data interpretation, 769-772
- mixed venous blood analysis, 772-775
- pulmonary edema, heart or lung, 775-776
- technique, 765-769
- monitoring in severe pregnancy-induced hypertension, 781-799
- complicated versus uncomplicated severe preeclampsia, 781-783
- intravascular volume and hemodynamic stability, 783-787
- pulmonary artery catheterization, 787-788
- in severe preeclampsia, 788-792
- volume expansion, 792-796
- with structural cardiac disease, 695-700
- aortic stenosis, 699-700
- mitral stenosis, 698-699
- subsets in severe preeclampsia, 793-795
- in VVLBW infants, 327-338
- arterial blood pressure, 330-333
- M-mode echocardiogram, 334-337
- neonatal heart rate, 327-330
- transcutaneous oxygen and carbon dioxide measurements, 334
- Hemorrhage, intracranial and other sites, and outcome of 501- to 1000-gm newborns, 277-279, 282-283
- Hemorrhagic shock in obstetrics, 755-763
- causes of, 755-757
- placenta previa, 756
- placental abruption, 755-756
- uterine rupture, 756-757
- hypovolemic shock management, 757-762
- physiologic changes in preparation for blood loss, 757
- Hemostasis, changes in pregnancy, 722-723
- regulation in thromboembolic disease, 720-722
- Heparin, anticoagulation in thromboembolic disease, 728-731
- with intravenous lipid emulsions, 154
- Hepatic lipase, 136
- Herbicide teratogenicity, 663
- Histidine, 102-103

- Hormones, fetal, and intrauterine growth, 11, 12
- Host resistance factors, in breast-feeding, 112-113
- Human malformations, problems of, 491-503
 education and miseducation, 501
 epidemiology, 492-493
 etiology of congenital malformations, 493-495
 prevention and treatment, 496-501
 teratogenesis mechanisms, 495-596
- Human milk. *See Milk(s), human.*
- Hyperglycemia, and betamimetic therapy for preterm labor inhibition, 850
 in tiny infants, 359-371
 clinical implications of, 361-362
 definition of, 359-360
 etiologic factors, 362-363
 incidence of, 360-361
 pathogenesis of, 364-368
 therapy for, 368-371
- Hyperinsulinemia in pregnancy, 58
- Hypernatremia in VVLBW infants, 385
- Hyperplasia, growth, 4-5
- Hypertension, pregnancy-induced, colloid osmotic pressure values, 835-836
 vasodilator effects, 784-785
 See also Hemodynamics, monitoring in severe pregnancy-induced hypertension.
- Hypertrophy, growth, 5
- Hypoglycemia in tiny infants, 351-359
 clinical implications of, 355
 definition of, 352
 etiologic factors, 353-355
 incidence of, 352-353
 pathogenesis of, 353-357
 therapy for, 357-359
- Hypolactasia, adult-type, 48
- Hyponatremia in VVLBW infants, 384
- Hypotension, and betamimetic therapy for preterm labor inhibition, 850-851
- Hypovolemic shock. *See Hemorrhagic shock in obstetrics.*
- Immune function, effect of lipid emulsions, 151-152
- Immunologic factors, in breast-feeding, 112-113
- Incidence of birth defects, 546-550
- Indomethacin, and premature kidney function, 393
- Infant Mortality Rate (IMR), definition of, 235
- Infants less than 1000 grams. *See Very low birth weight infants.*
- Infectious agents, teratogenicity of, 672-673
- Inflammatory bowel disease, total parenteral nutrition in, 68
- Information sources, in medicolegal cases, 513-514
- Inotropic support, in septic shock, 747-748
- Insulin growth factors, 60
- Interstitial fluid, colloid osmotic pressure, normal values, 831-833
- Intestinal adaptation, in short bowel syndrome, 167-168
- Intralipid, 133-134
- Intrapartum care, of sickle cell crisis, 863
 of thromboembolic disease, 732-733
- Intrauterine growth retardation (IUGR)m 3, 75-76
 antenatal management in, 24-25
 asymmetric, 7-8
 etiology of, 5-9
 and outcome of 501- to 1000-gm newborns, 271, 273-275, 281
 symmetric, 5-7
- Intrauterine volume, 20-21
- Intravenous therapy, with lipid emulsions, 133-162
- Iodine deficiency, and teratogenesis, 670
- Iron loss, in short bowel syndrome, 166
- Isoleucine, 98-100
- Kidney, and betamimetic therapy for preterm labor inhibition, 845-847
 See also Renal function.
- Labor, obstetric management of, in preterm delivery, 258-259
 preterm inhibition. *See Betamimetic therapy.*
- Laboratory aids, for sickle cell diagnosis, 857-858
- Lactase deficiency, primary congenital, 48
- Lactation, establishment and maintenance of, 115-118
- Lactogen, human placental, 15
- Lactose intolerance, severe familial, 48
- Larynx malformations in thalidomide syndrome, 569
- Law, and congenital malformations, 505-544
 expert witness, 529-538
 case studies, 530-536
 quality of testimony, 537-538
 responsibility failures, 536-537
 lawsuits, nature of, 516-529
 attorney for plaintiff, 523-525
 case histories, 517-520
 defendant, 522
 medical care and legal systems, 525-526
 patient as plaintiff, 520-522
 physician expert witness, 522-523
 recommendations, 527-529

Law (*Continued*)

- legal issues, 505-516
 - classification of congenital malformations, 510-512
 - defendant, 507
 - etiology of congenital malformations, 508-509
 - expert witness, 508
 - information sources, 513-514
 - legislation, 514-515
 - medicolegal work-up, 512-513
 - plaintiff, 507
 - responsibility in negligence cases, 509-510
 - sensitive period, oversimplification of, 509
- Lecithin-cholesterol acyltransferase (LCAT), 136-137
 - in preterm infants, 144
- Legislation, and congenital malformations, 514-515
- Length measurements, in premature infants, 79-81
- Leucine, 98-101
- Limb reduction defects, 575-591
 - family history, 576-577
 - teratogenic history, 577-578
 - uterine environments, 578-585
 - amnion rupture, 582-585
 - ectopic tubal gestation, 578-579
 - structural anomalies, 579-582
 - and vascular disruption, 585-589
- Limb and limb girdle malformations in thalidomide syndrome, 558-567
- Lipids, catabolism, role of carnitine, 142-144
 - clearance, enzymes, cofactors, and sites of, 138
 - in newborn infant, 137-139
 - dosage, increasing, 139-141
 - emulsions, and bilirubin binding, 147-149
 - and coagulation and platelet function, 153
 - and glucose metabolism, 147
 - heparin administration with, 154
 - and immune function, 151-152
 - infusion rate for, 153-154
 - intravenous administration of, 133-162
 - and laboratory tests, 155-156
 - lipid concentration for, 155
 - monitoring during infusion of, 155
 - and oxygenation, 150-151
 - and pulmonary vasculature, 149-150
 - soybean oil vs. safflower oil, 154-155
 - metabolism, during pregnancy, 59
 - in VVLBW infants, nutritional requirements, 436
 - in parenteral nutrition, 426-430
 - Lipid system, glucose system vs., 145-146
 - Lipolytic activity, post heparin, 134-135
 - Lipoprotein, triglyceride, intravascular vs. endothelial hydrolysis of, 142, 143
 - Lipoprotein lipase, 135-136
 - Lithium carbonate teratogenicity, 663-664
 - Liver disease, total parenteral nutrition in, 172
 - Liver dysfunction, and parenteral nutrition, 197-212
 - Low birth weight, United States rate, 236-237
 - Lung, compliance in VVLBW infants, 306-307
 - malformations in thalidomide syndrome, 569
 - maturation, in very low birth weight fetus, 257-258
 - in VVLBW infants, 285-286
 - resistance in VVLBW infants, 307
 - scanning, in thromboembolic disease, 727
 - Lysine, 101
 - Macrosomic newborns, 75-78
 - Magnesium loss, in short bowel syndrome, 166
 - Malformations, congenital, frequency of, 545-554
 - birth defects and infant mortality, 545-546
 - Down's syndrome, 550
 - etiology, 550-552
 - exposure/case definitions, 552-553
 - identification of human birth defects, 552-553
 - incidence, 546
 - neural tube defects, 550
 - trends in incidence, 546-550
 - and the law, 505-544
 - expert witness, 529-538
 - case studies, 530-536
 - failures of responsibility, 536-537
 - quality of testimony, 537-538
 - lawsuit types, 516-529
 - attorney for plaintiff, 523-525
 - case histories, 517-520
 - defendant, 522
 - medical care and legal systems, 525-526
 - patient as plaintiff, 520-522
 - physician expert witness, 522-523
 - recommendations, 527-529
 - legal issues in teratology, 505-516
 - classification of congenital malformations, 510-512
 - defendant, 507-508
 - etiology of congenital malformations, 508-509
 - expert testimony, 508
 - information sources, 513-514

- legislation, 514-515
- medicolegal work-up, 512-513
- plaintiff, 507
- prevention of medicolegal problems, 513-515
- responsibility in negligence cases, 509-510
- sensitive period, oversimplification of, 509
- in thalidomide syndrome, 558-570
 - abdomen, 570
 - growth, 567
 - heart, circulation, and blood vessels, 569-570
 - internal organs, 569
 - limbs and limb girdle, 558-567
 - skull and teeth, 568
 - special senses and cranial nerves, 568-569
 - spine, 567
- thalidomide-type, 570-572
- ultrasound diagnosis *in utero*, 593-607
 - absence of normally present structure, 593-596
 - dilatation behind obstruction, 598-599
 - fetal biometry, 599-601
 - fetal motion abnormalities, 602
 - herniations through structural defects, 597-598
 - presence of additional structure, 596-597
- See also *Human malformations*.
- Malnutrition, maternal, and fetal outcome, 61-63
 - problems associated with, 57
 - protein energy, 78-79
 - biochemical tests in, 83-84
- Maternal conditions, and teratogenesis, 671-672
- Maternal risk factors, and fetal growth, 14
- Medical care, and legal system, 525-526
- Medicolegal work-up, 512-513
- Metabolic bone disease, in VVLBW infants, 437-438
- Metabolism, maternal, normal, 58-59
- Methionine, 102
- Methotrexate teratogenicity, 660
- 3-Methyl histidine, in assessment of protein degradation and nitrogen balance, 93
- creatinine, ratio, in amniotic fluid, 15-16
- Methylmercury teratogenicity, 664
- Microwave effects on embryo and fetus, 615-648
 - teratogenic and carcinogenic effects, 642-643
- Midarm circumference, head circumference ratio, 76-78
 - in premature infants, 81, 82
- Milk(s), human, analysis of composition of, 95
 - banked, 111
 - cellular components, 113
 - composition of, variability, 114
 - contaminants and toxins in, 117-118
 - ejection of, 116
 - for neonates, 92
 - fortifiers, 115
 - immunologic factors in, 112-113
 - nutritional adequacy, for premature infants, 113-115
 - for VVLBW infants, 436-438
- Mitral stenosis, during pregnancy, 698-699
- M-mode echocardiogram, 334-337
- Monosaccharide, acquired intolerance for, 46
 - transport defects, 42, 46
- Morbidity, and long-term outcome, 245-246
- Mortality rates, and birth defects, 545-546
 - and colloid osmotic pressure values, 839-840
 - of VVLBW infants, literature survey, 453
- perinatal, 270
 - postneonatal rates, 244-245
 - survey of centers, 454-457
- Motion, fetal, ultrasound diagnosis, 602
- Myocardial infarction, in pregnancy, 702
- Myocardial ischemia, and betamimetic therapy for preterm labor inhibition, 847-848
- Negligence cases, responsibility in, 509-510
- Neonatal Mortality Rate (NMR), definition of, 235
 - race and weight-specific rates, 240-241
 - of very very low birth weight infants, 241-242
- Neonate(s), full term, optimal food for, 92
 - growth-retarded, 75-76
 - large for gestational age, 77
 - lipid clearance in, 137-139
 - macrosomic, 76-78
 - malnourished, symptoms of, 74
 - nutritional assessment of, 73-89
 - optimal nutrition for, 91
 - premature, breast-feeding of, 111-122
 - fallacy of normal fetal growth in, 13
 - growth in, longitudinal assessment of, 78
 - postnatal growth of, 74-75
 - small for gestational age, 9, 10, 75-76
- Neural tube defects, 550
- Newborns. See *Neonates*.
- Nicotine teratogenicity, 674
- Nitrogen, accumulation in newborn, 123
 - balance, in premature infants, 92-93
 - positive, promotion of, 145
 - technique of, 124-125
- in human milk, 115
- losses, 92

- Nitrogen (*Continued*)
 requirement for growth, 125
 sources, for parenteral nutrition, 91-109
¹⁵N methods in protein requirements studies, 128
 Noninfectious agents, preconception exposure to, 675
 Nonprescription drugs and products, teratogenicity of, 673-674
 Nutrition, assessment of, in pregnancy, 63-65
 enteral, in pregnancy, 65
 fetal, methods for assessing, 80
 maternal, normal, 58-59
 optimal, for neonate, 91
 parenteral, and liver dysfunction, 91-109, 197-212
 placental role in, 59-61
 total parenteral. *See Total parenteral nutrition.*
 in VVLBW infants, 419-443
 in bronchopulmonary dysplasia, 320
 enteral nutrition, 431-432
 goals of, 419-420
 metabolic bone disease, 437-438
 nutritional requirements, 432-438
 carbohydrates, 436
 fat, 436
 human milk, 436-438
 protein, 433-435
 vitamins and trace metals, 438
 parenteral nutrition, 420-431
 calcium and phosphorus, 430
 carbohydrate, 425-426
 cholestasis, 430-431
 goals, 422
 lipid, 426-430
 protein, 422-425
 vitamins and trace minerals, 430
 Nutritional assessment, of neonate, 73-89
 Nutritional intake, measurement, 85
 Nutritional status, assessment, 85
- Obstetric care, amniotic fluid embolism, 801-811
 clinical presentation, 807
 coagulopathy, 806
 diagnosis, 808
 experimental models, 802-804
 historical considerations, 801-802
 human data, 804-806
 management protocol, 808-809
 treatment, 808
 betamimetic therapy for preterm labor inhibition, 843-852
 cardiac arrhythmias, 848-849
 cerebral ischemia, 849-850
 circulatory system, 843
 hyperglycemia, 850
 hypotension, 850-851
 myocardial ischemia, 847-848
 pulmonary edema, 844-845
 renal function, 845-847
 cardiac disease, structural, 695-703
 hemodynamic changes, 695-700
 myocardial infarction, 702
 prophylaxis for bacterial endocarditis, 702-703
 pulmonary hypertension, 700-702
 colloid osmotic pressure, use of in pregnancy, 827-842
 calculation and measurement, 829-831
 clinical applications, 836-839
 collection techniques, 831
 definition of, 827-828
 and fluid therapy, 833-834
 mortality, 839-840
 normal values in blood and interstitium, 831-833
 in postpartum period, 834
 in pregnancy-induced hypertension, 835-836
 Starling's law, 828-829
 and tocolytic therapy, 835
 for disseminated intravascular coagulation, 705-717
 amniotic fluid embolus, 714-716
 diagnosis, 708-709
 fetal death syndrome, 713-714
 pathophysiology, 707
 placental abruption, 711-712
 preeclampsia, 710-711
 septic abortion, 712-713
 treatment, 709-710
 fatty liver of pregnancy, 813-825
 clinical presentation, 819-821
 differential diagnosis, 817-818
 historical perspective, 813-814
 pathogenesis, 814-815
 pathology, 816-817
 pathophysiology, 815-816
 treatment, 821-823
 hemodynamic monitoring in severe hypertension, 781-799
 complicated versus uncomplicated severe preeclampsia, 781-783
 epidural analgesia and antihypertensive therapy, 786-787
 intravascular volume and hemodynamic stability, 783-787
 oliguria, 782
 preeclampsia, uncomplicated, 782-783
 pulmonary artery catheterization, 787-788
 pulmonary edema, 781-782
 severe preeclampsia, 788-792
 vasodilators, 784-786
 volume expansion, 785, 792-796
 volume manipulation, 784

- hemorrhagic shock, 755-763
causes of, 755-757
hypovolemic shock management, 757-762
physiologic changes in preparation for blood loss, 757
- invasive hemodynamic monitoring, 765-779
cardiovascular monitoring and obstetrics, 776-777
clinical investigations, 777
data collection, 768-769
data interpretation, 769-772
mixed venous blood analysis, 772-775
pulmonary edema, 775-776
technique, 765-769
- issue on, 695-698
- septic shock, 741-754
adult respiratory distress syndrome, 748
antimicrobial therapy, 748-749
clinical manifestations, 745-746
controversial treatment modalities, 751-752
etiology, 741-742
management of, 746-751
pathophysiology, 742-744
surgical treatment, 749
- sickle cell crisis, 853-868
clinical presentation, 853-854
differential diagnosis, 857-858
management, 858-864
new developments, 864
pathophysiology, 854-856
- and thromboembolic disease, 719-739
adjunctive measures and symptomatic treatment, 734
diagnosis of deep venous thrombosis, 723
diagnosis of pulmonary thromboembolism, 726
hemostasis changes, 722-723
hemostasis regulation, 720-722
heparin anticoagulation, 728-731
¹²⁵I fibrinogen scanning, 725
incidence, 719
intrapartum and postpartum considerations, 732-733
lung scanning, 727
noninvasive examinations, 724-725
pulmonary arteriography, 727-728
surgical intervention, 734
thromboembolism, prophylaxis of, 734-735
thrombolytic therapy, 733-734
venography, 723-724
warfarin anticoagulation, 731-732
- and very low birth weight fetus, 251-265
lung maturation, 257-258
corticosteroid use, 257-258
thyroid hormone effects, 258
- preterm delivery, 258-261
delivery management, 259-261
labor management, 258-259
premature twin gestation, 261
tocolysis in preterm labor, 252-257
- Odds Ratio, 235
- Oliguria, in severe preeclampsia, 782
- Outcome of VVLBW infants, 451-459
morbidity rates, 245-246
- Ovary, and diagnostic or therapeutic radiation, 640-642
- Oxazolidine-2,4-diones (trimethadione, parame-thadione), teratogenicity of, 664-665
- Oxygen, in bronchopulmonary dysplasia in tiny infant, 317
and fetal growth, 191-196
in hemorrhagic shock, 758
and lipid emulsions, 150-151
transcutaneous measurements in VVLBW infants, 334
- Oxytocin, in lactation, 116-117
- Oxytocinase, 17
- Pancreatic amylase deficiency, 49-50
- Parenteral nutrition, nitrogen sources for, 91-109
- Patent ductus arteriosus, and assisted ventilation in VVLBW infants, 291-292
- Patient as plaintiff, 520-522
- Perinatal factors for 501- to 1000-gm newborns, 267-284
birth weight, 280-281
fetal deaths versus neonatal survivors, 271-273
amnionitis, 273, 281-282
cord prolapse, 271, 281
intrauterine growth retardation, 271
presentation, 271
mortality, 270
neonatal deaths versus neonatal survivors, 273-276
fetal distress, 275, 282
intrauterine growth retardation, 273-275, 281
pre-eclampsia, 273, 282
presentation and mode of delivery, 275-276, 281
neonatal factors and neonatal survivors, 276-279
Apgar scores, 277, 282
gastrointestinal disorders, 279, 283
hemorrhage, intracranial and other, 277-279, 282-283
RDS/HMD, 277, 282
renal failure, 279, 283
seizures, 277, 283

- Perinatal factors for 501- to 1000-gm newborns (*Continued*)
- University of Illinois Perinatal Data Collection System, 268
 - data collection, 268-270
 - statistical analysis, 270
 - Perinatal mortality rate (PMR), 235
 - Phenylalanine, 102
 - Phi coefficient, 235
 - Philadelphia growth curve, 9, 10
 - Phosphatidylglycerol, and foam stability index, 18-19
 - Phosphorus levels, in human milk, 115
 - in parenteral nutrition, 430
 - in VVLBW infants, 386-387
 - Physician as expert witness, 522-523
 - Placenta, abruption, and disseminated intravascular coagulation, 711-712
 - in hemorrhagic shock, 755-756
 - previa, in hemorrhagic shock, 756
 - role in nutrition, 59-61
 - Placental grading, 22
 - Plaintiff, attorney for, 523-525
 - in congenital malformation lawsuits, 507
 - patient as, 520-522
 - Plasma proteins, as indicators of protein energy nutrition, 94-95
 - Platelet function, effect of lipid emulsions on, 153
 - Pneumotachography in VVLBW infants, 303-306
 - airflow, 306
 - airway pressure, 305
 - esophageal pressure, 304-305
 - instrumentation, 303-304
 - volume, 306
 - Pneumothorax in VVLBW infants, 292-293
 - Polychlorinated biphenyl teratogenicity, 665-666
 - Ponderal index(ices), applications of, 82-83
 - intrauterine, 22-23
 - Postheparin lipolytic activity (PHLA), 134-135
 - Postneonatal mortality rate (PNMR), 235
 - Postpartum care, and colloid osmotic pressure values, 834
 - of sickle cell crisis, 864
 - of thromboembolic disease, 732-733
 - Potassium excretion, in VVLBW infants, 387
 - Prealbumin, as indicator of protein synthesis, 94
 - in newborns with septicemia, 83-84
 - Preeclampsia, and disseminated intravascular coagulation, 710-711
 - and outcome of 501- to 1000-gm newborns, 273, 282
 - plasma volume in, 785
 - and pulmonary edema, 781-782
 - severe, hemodynamic measurement, 788-792
 - cardiac function curves, 790
 - cardiac output and systemic vascular resistance, 791
 - central venous pressure and pulmonary capillary wedge pressure, 788-790
 - regional perfusion associated with "high" cardiac output, 793
 - hemodynamic subsets, 793-795
 - high cardiac output hypertension, 792-793
 - and severe oliguria, 782
 - uncomplicated, hemodynamic monitoring, 782-783
 - uncomplicated severe, and pulmonary artery catheterization, 795-796
 - vasodilator treatment, 786
 - volume expansion, 785, 792-796
 - Pregnancy, blood loss, physiologic changes in preparation for, 757
 - normal nutrition and metabolism during, 58-59
 - outcome, effects of maternal malnutrition on, 61-63
 - ovarian and uterine exposure to diagnostic or therapeutic radiation, 640-642
 - pulmonary capillary wedge pressure, normal values, 789
 - radiation effects, 634-649
 - total parenteral nutrition during, 57-72
 - clinical experience with, 67-70
 - See also *Obstetric care*.
 - Preload, in invasive hemodynamic monitoring, 769-771
 - Prematurity prevention, and "nine by ninety," 246-248
 - Presentation and mode of delivery, and outcome of 501- to 1000-gm newborns, 271, 275-276, 281
 - Pressure, in severe pregnancy-induced hypertension central venous, 787-789
 - pulmonary capillary wedge, 787-790
 - See also *Colloid osmotic pressure*.
 - Progestin teratogenicity, 666-667
 - Prolactin, in lactation, 115-116
 - Prophylaxis of thromboembolism, 734-735
 - Prostaglandins, and premature kidney function, 394
 - Protein(s), excess, adverse consequences of, 123-124
 - in human milk, 114-115
 - nutritional requirements of VVLBW infants, 433-435
 - in parenteral nutrition of VVLBW infants, 422-425
 - plasma, as indicators of protein energy nutrition, 94-95
 - pregnancy-associated plasma, 17-18
 - requirements, estimation from balance studies, 124-125

- in neonates, 91-95
- in pregnancy, 59
- methods for determining, 123-132
- serum, determination of, 130-131
- therapy, in short bowel syndrome, 168
- turnover, estimation of, with ^{14}C -amino acids, 129
- Protein energy malnutrition, 78-79
 - biochemical tests in, 83-84
- Pulmonary arteriography, in thromboembolic disease, 727-728
- Pulmonary artery catheterization. *See* *Catheterization*.
- Pulmonary capillary wedge pressure, and colloid osmotic pressure, 836-837
 - in pregnancy-induced hypertension, 787-790
- Pulmonary edema, and betamimetic therapy for preterm labor inhibition, 844-845
- invasive hemodynamic monitoring, 775-776
 - in severe preeclampsia, 781-782
- Pulmonary function in VVLBW infants, 299-313
 - current methods of assessment, 308-311
 - future considerations, 311
 - lung compliance, 306-307
 - lung resistance, 307
 - past methods of assessment, 300-303
 - pneumotachography, 303-306
 - airflow, 306
 - airway pressure, 305
 - esophageal pressure, 304-305
 - instrumentation, 303-304
 - volume, 306
- Pulmonary hypertension, during pregnancy, 700-702
- Pulmonary interstitial emphysema, in VVLBW infants, 292-293
- Pulmonary thromboembolism, diagnosis of, 726
- Pulmonary vasculature, lipid emulsion effects, 149-150
- Pulsatility index, 23-24
- Race, and weight-specific death rates, 240-241
- Radiation, ionizing, teratogenic and carcinogenic effects, 617-643, 667-668
- Radioiodine teratogenicity, 670
- RDS/HMD, and outcome of 501- to 1000-gm newborns, 277, 282
- Renal function in VVLBW infants, 377-401
 - acid-base homeostasis, 385
 - aminoglycoside effects, 394-395
 - and artificial ventilation, 389-390
 - calcium and phosphate homeostasis, 386-387
 - and drugs given to mother, 390-391
 - and drugs given to neonate, 391-394
 - electrolyte and solute excretion, 387-388
 - glomerular filtration development, and renal perfusion, 378-382
 - intrauterine maturation, 377-378
 - and outcome of 501- to 1000-gm newborns, 279, 283
 - during respiratory distress syndrome, 388-389
 - syndrome of inappropriate antidiuretic hormone secretion, 390
 - water and sodium balance, 382-385
 - hypernatremia, 385
 - hyponatremia, 384
- Respiratory distress syndrome, and outcome of 501- to 1000-gm newborns, 277, 282
- and renal function in VVLBW infants, 388-389
- Resuscitation and respiratory management of VVLBW infants, 285-297
 - assisted ventilation, 288-293
 - monitoring during, 289-291
 - problems during, 291-293
 - bronchopulmonary dysplasia, 293-294
 - delivery room management, 286-288
 - extrapulmonary complications, 294
 - lung development, 285-286
 - surfactant therapy, 294-295
- Retinol-binding protein, 94-95
- Safflower oil lipid emulsions, 154-155
- Schwangerschaft's protein I, 17-18
- Seizures, neonatal, and outcome of 501- to 1000-gm newborns, 277, 283
- Septic shock in obstetrics, 741-754
 - clinical manifestations, 745-746
 - controversial treatment modalities, 751-752
 - etiology, 741-742
 - management of, 746-751
 - adult respiratory distress syndrome, 748
 - antimicrobial therapy, 748-749
 - general treatment measures, 749-751
 - inotropic support, 747-748
 - intravascular volume correction, 747
 - surgical treatment, 749
 - pathophysiology, 742-744
- Shock. *See* *Hemorrhagic shock*; *Septic shock*.
- Short bowel syndrome, 163-173
 - anatomic and operative management options in, 169-170
 - etiology of, 164-165
 - intestinal adaptation in, 167-168
 - management plan for, 170-171
 - nutritional and medical management of, 168-169
 - outcome of, 171-172
 - pathophysiology of, 165-167

- Sickle cell crisis in pregnancy, 853-868
 clinical presentation, 853-854
 differential diagnosis, 857-858
 laboratory aids, 857-858
 therapeutic measures, 858
 management, 858-864
 antepartum care, 858-862
 intrapartum care, 863
 postpartum care, 864
 new developments, 864
 pathophysiology, 854-856
- Skull and teeth malformations in thalidomide syndrome, 568
- Small for gestational age infants, 9, 10, 75-76
- Small intestine, development of disaccharidases in, 38-41
 sarcoma of, total parenteral nutrition in, 68
- Smoking, and growth-retarding mechanisms, 8-9
 and teratogenesis, 674
- Sodium and water balance, in VVLBW infants, 382-385
- Soybean oil lipid emulsions, 154-155
- Special senses, malformations in thalidomide syndrome, 568-569
- Spine malformations in thalidomide syndrome, 567
- Stable isotope techniques, evaluation of, 129-130
 protein requirement and, 125-131
- Starling's law, 828-829
- Starvation, maternal, 671
- Steroids, in bronchopulmonary dysplasia in tiny infants, 321
- Substance abuse: street drugs, teratogenicity of, 668
- Sucrase-isomaltase deficiency, congenital, 48-49
- Sudden infant death syndrome, 3
- Surfactant therapy in VVLBW infants, 294-295
- Surgery, problems and outcome in VVLBW infants, 445-451
 in septic shock, 749
 for thromboembolic disease, 734
- Syndrome of inappropriate antidiuretic hormone secretion, 390
- Tachycardia in tiny premature infant, and premature beats, 341
 supraventricular, 341-343, 348
 ventricular, 343, 349
- Taurine, 103
- Teratogenesis, alcohol, 654-659
 aminopterin, 660
 androgens, 660
 antineoplastic drugs, 659-660
 aspirin, 673-674
 caffeine, 674
 coumarin derivatives, 661
 cyclophosphamide, 661-662
 diethylstilbesterol, 662
 diphenylhydantoin, 662-663
 herbicides: Agent Orange, 663
 infectious agents, 672-673
 limb reduction defects, 577-578
 lithium carbonate, 663-664
 maternal conditions, 671-672
 maternal starvation, 671
 mechanical problems, 670-671
 mechanisms of, 495-496, 649-654
 methotrexate, 660
 methylmercury, 664
 oxazolidine-2,4-diones (trimethadione, paramethadione), 664-665
 polychlorinated biphenyls, 665-666
 progestins (female sex hormones), 666-667
 radiation, 667-668
 smoking and nicotine, 674
 substance abuse: street drugs, 668
 tetracycline, 669
 thalidomide, 669-670
 thyroid: iodine deficiency, iodides, radioiodine, anti-thyroid drugs, 670
 vitamins, 674
- Teratology, of environmental agents, 609-613
 animal testing, 610-611
 classification, 609-610
 evaluation methods, 611-612
 issue on, 491-687
 legal issues, 505-516
 classification of congenital malformations, 510-512
 communication aspects, 513
 defendant, 507-508
 etiology of congenital malformations, 508-509
 expert witness, 508
 information sources, 513-514
 legislation, 514-515
 medicolegal work-up, 512-513
 plaintiff, 507
 responsibility in negligence cases, 509-510
 sensitive period, oversimplification of, 509
- Terminology in thalidomide syndrome, 555-556
- Tetracycline teratogenicity, 669
- Thalidomide syndrome, 555-573
 clinical patterns, 556-558
 exposure risks, 556
 malformation types, 558-570
 abdomen, 570

- growth, 567
- heart, circulation, and blood vessels, 569-570
- internal abnormalities, 569
- limbs and limb girdle, 558-567
- skull and teeth, 568
- special senses and cranial nerves, 568-569
- spine, 567
- terminology, 555-556
- thalidomide-type deformities, 570-572
- Thalidomide teratogenicity, 669-670
- Threonine, 101
- Thromboembolic disease in pregnancy, 719-739
 - adjunctive measures and symptomatic treatment, 734
 - diagnosis of deep venous thrombosis, 723
 - hemostasis changes, 722-723
 - hemostasis regulation, 720-722
 - heparin anticoagulation, 728-731
 - ¹²⁵I fibrinogen scanning, 725
 - incidence, 719
 - intrapartum and postpartum considerations, 732-733
 - lung scanning, 727
 - noninvasive examinations, 724-725
 - prophylaxis of thromboembolism, 734-735
 - pulmonary arteriography, 727-728
 - pulmonary thromboembolism, diagnosis of, 726
 - surgical intervention, 734
 - thrombolytic therapy, 733-734
 - venography, 723-724
 - warfarin anticoagulation, 731-732
- Thrombolytic therapy, for thromboembolic disease, 733-734
- Thrombosis, deep venous, diagnosis of, 723
- Thyroid hormone, role in lung maturation, 258
 - teratogenicity, 670
- Time-dependent formula, 3-4
- Tocolytic therapy, and colloid osmotic pressure, 835
 - in preterm labor, 252-257
- Tolazoline, and premature kidney function, 393-394
- Total parenteral nutrition, advantages of, 66 and home care, 213-226
 - complications of, 67, 69
 - diseases treated with, 66
 - liver disease associated with, 172
 - during pregnancy, 57-72
 - clinical experiences with, 67-70
 - for premature newborn, 66
 - in short bowel syndrome, 169-171
 - techniques of, 67
- Trace element deficiencies, in short bowel syndrome, 166, 168-169
- Transport deficiencies, 46-50
- Trehalase deficiency, 48
- Triceps skinfold thickness, 78
 - of premature infants, 81-82
- Triglyceride, hydrolysis and clearance of, from circulation, 134-137
 - lipoprotein, intravascular vs. endothelial hydrolysis of, 142, 143
- Tryptophan, 101-102
- Twin gestation, premature, delivery management of, 261
- Tyrosine, 102
- Ultrasound, embryonic and fetal exposure to, 615-648
 - teratogenic and carcinogenic effects, 642-643
 - in evaluation of fetal growth, 19-24
 - in utero* diagnosis of congenital malformation, 593-607
 - absence of normally present structure, 593-596
 - dilatation behind obstruction, 598-599
 - fetal biometry, 599-601
 - fetal motion abnormalities, 602
 - presence of additional structure, 596-597
- University of Illinois Perinatal Data Collection System, 268-270
- Uric acid excretion, in VVLBW infants, 387
- Urine production, fetal, 22
- Uterus, and diagnostic or therapeutic radiation, 640-642
 - and limb reduction defects, 578-585
 - amnion premature rupture, 582-585
 - ectopic tubal gestation, 578-579
 - structural anomalies, 579-582
 - rupture of, and hemorrhagic shock, 756-757
- See also *Ultrasound*.
- Valine, 98
- Vascular disruption, and limb reduction defects, 585-589
- Vasodilators, in hypertension, 784-785
 - in severe preeclampsia, 786
- Venography, for thromboembolic disease, 723-724
- Ventilation, assisted, in VVLBW infants, 288-293
 - monitoring during, 288-291
 - problems during, 291-293
 - and renal function, 389-390
- Ventilator and oxygen supplementation, in bronchopulmonary dysplasia, 319-321
- Ventricular contractions, premature, in tiny premature infant, 343

- Very low birth weight infants, arrhythmias in, 339-350
- bradyarrhythmias, 340-341
 - bradycardia, 347-348
 - fetal arrhythmias, 345-347
 - intraventricular conduction defects, 343
 - management of, 347
 - mechanism and etiology, 339
 - premature atrial contractions, 341
 - premature beats and tachycardias, 341
 - premature ventricular contractions, 343
 - supraventricular tachycardia, 341-343
 - supraventricular tachycardia, 348
 - ventricular tachycardia, 343
 - ventricular tachycardia, 349
- epidemiologic study of, 233-250
- frequency of, 237-238
- obstetric management of, 251-265
- delivery, 259-261
 - labor, 258-259
 - lung maturation, 257-258
 - premature twin gestation, 261
 - tocolysis in preterm labor, 252-257
- perinatal factors influencing outcome, 267-284
- University of Illinois Perinatal Data Collection System, 268-270
- place of birth for, 244
- Very very low birth weight (VVLBW) infants, body fluid compartments in, 403-417
- data review, 405-416
 - methodology, 403-405
- bronchopulmonary dysplasia in, 315-326
- history and definition, 315-319
 - long-term outcome, 324
 - management of, 320-322
 - nutrition, 320
 - postdischarge management, 322-324
 - supportive care, 320
 - ventilator and oxygen supplementation, 319-320
- cost of care of, 461-476
- cost-benefit analysis, 474-475
- enteral nutrition, 431-432
- epidemiologic study of, 233-250
- ethical issues in caring for, 477-484
- frequency of, 237-238
- hemodynamics in, 327-338
- arterial blood pressure, 330-333
 - M-mode echocardiogram, 334-337
 - neonatal heart rate, 327-330
 - transcutaneous oxygen and carbon dioxide measurements, 334
- hospitalization length, 465-466
- hyperglycemia in, 359-371
- clinical implications of, 361-362
 - definition of, 359-360
 - etiological factors, 362-363
 - incidence of, 360-361
 - pathogenesis of, 364-368
 - therapy for, 368-371
- hypoglycemia in, 351-359
- clinical implications of, 355
 - definition of, 352
 - etiological factors, 353-355
 - incidence of, 352-353
 - pathogenesis of, 355-357
 - therapy for, 357-359
- less than 500-gm births, 242-244
- mortality, literature survey, 453
- survey of centers, 452-455
 - and survival, 466-467
- Neonatal Mortality Rates, 241-242
- nutritional requirements, 432-438
- carbohydrates, 436
 - fat, 436
 - human milk, 436-438
 - protein, 433-435
 - vitamins and trace metals, 438
- outcome of, 453-459
- environmental influences, 460
- parenteral nutrition, 420-431
- calcium and phosphorus, 430
 - carbohydrate, 425-426
 - cholestasis, 430-431
 - goals of, 422
 - lipid, 426-430
 - protein, 422-425
 - vitamins and trace minerals, 430
- perinatal factors influencing outcome, 267-284
- amnionitis, 273, 281-282
 - Apgar scores, 277, 282
 - birth weight, 280-281
 - cord prolapse, 271, 281
 - fetal distress, 275, 282
 - gastrointestinal disorders, 279, 283
 - hemorrhage, intracranial and other sites, 277-279, 282-283
 - intrauterine growth retardation, 271, 273-275, 281
 - mortality rates, 270
 - neonatal seizures, 277, 283
 - pre-eclampsia, 273, 282
 - presentation and mode of delivery, 271, 275-276, 281
 - RDS/HMD, 277, 282
 - renal failure, 279, 283
- pulmonary function in, 299-313
- current methods of assessment, 308-311
 - future considerations, 311
 - lung compliance, 306-307
 - lung resistance, 307
 - past methods of assessment, 300-303
 - pneumotachography, 303-306
- renal function in, 377-401
- acid-base homeostasis, 385
 - aminoglycoside effects, 394-395

- and artificial ventilation, 389-390
- calcium-phosphate homeostasis, 386-387
- and drugs given to mother, 390-391
- and drugs given to neonate, 391-394
- electrolyte and solute excretion, 387-388
- glomerular filtration development, and renal perfusion, 378-382
- intrauterine maturation, 377-378
- during respiratory distress syndrome, 388-389
- syndrome of inappropriate antidiuretic hormone secretion, 390
- water and sodium balance, 382-385
- resuscitation and respiratory management in, 285-297
- assisted ventilation, 288-293
- bronchopulmonary dysplasia, 293-294
- cardiopulmonary problems, 291-292
- delivery room management, 286-288
- extrapulmonary complications, 294
- lung development, 285-286
- pulmonary interstitial emphysema and pneumothorax, 292-293
- surfactant therapy, 294-295
- surgical problems and outcome in, 445-451
- Vitamins, deficiencies in short bowel syndrome, 166-167
- placental transfer of, 61
- teratogenicity of, 674
- therapy in short bowel syndrome, 168
- and trace metals in VVLBW infants, nutritional requirements, 438
- in parenteral nutrition, 430
- Volume expansion, in hypertension, 784
- Volume, intravascular, correction of, in septic shock, 747
- VVLBW infants. See *Very very low birth weight infants.*
- Warfarin anticoagulation, for thromboembolic disease, 731-732
- Water and sodium balance, in VVLBW infants, 382-385
- Weight(s), fetal, estimation of, 21
- measurement of, in nutritional assessment, 123
- Wet nursing, 111
- X-ray effects on embryo and fetus, 615-648
- counseling pregnant woman exposed to radiation, 634-649
- exposure from radiation therapy, 639-640
- human radiation teratogenesis, 619-628
- oncogenic effect of prenatal radiation, 628-634
- ovarian and uterine exposure to radiation, 640-642